Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quetiapine XR vs Escitalopram Effects on HPA Axis in Depression
NCT00953108Phase 3Completed
- Sponsor
- Ludwig Maximilian University of Munich
- Start
- Sep 2009
- Primary completion
- Feb 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of quetiapine in major depressive disorder (MDD) (2 arms), sponsored by Ludwig Maximilian University of Munich. Primary endpoint: Hypothalamic-pituitary-adrenocortical (HPA)-axis activity measured by serial dexamethasone/CRH tests at Week 5. Started Sep 2009; status: completed.
02
Drugs
quetiapine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT00953108.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00953108.